These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22589265)

  • 1. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
    van der Heijde D; Keystone EC; Curtis JR; Landewé RB; Schiff MH; Khanna D; Kvien TK; Ionescu L; Gervitz LM; Davies OR; Luijtens K; Furst DE
    J Rheumatol; 2012 Jul; 39(7):1326-33. PubMed ID: 22589265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies.
    Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2015 Jan; 25(1):11-20. PubMed ID: 24842476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
    Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
    Keystone EC; Curtis JR; Fleischmann RM; Furst DE; Khanna D; Smolen JS; Mease PJ; Schiff MH; Coteur G; Davies O; Combe B
    J Rheumatol; 2011 Jun; 38(6):990-6. PubMed ID: 21362764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.
    Curtis JR; Luijtens K; Kavanaugh A
    Arthritis Care Res (Hoboken); 2012 May; 64(5):658-67. PubMed ID: 22231904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
    Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
    Keystone EC; Combe B; Smolen J; Strand V; Goel N; van Vollenhoven R; Mease P; Landewé R; Fleischmann R; Luijtens K; van der Heijde D
    Rheumatology (Oxford); 2012 Sep; 51(9):1628-38. PubMed ID: 22596211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
    Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
    Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
    Strand V; Smolen JS; van Vollenhoven RF; Mease P; Burmester GR; Hiepe F; Khanna D; Nikaï E; Coteur G; Schiff M
    Ann Rheum Dis; 2011 Jun; 70(6):996-1002. PubMed ID: 21415050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.
    Saraux A; Flipo RM; Fagnani F; Massol J; Cukierman G; Joubert JM; Huot-Marchand P; Combe B
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.